MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.14 -3.17

Overview

Share price change

24h

Current

Min

2.08

Max

2.21

Key metrics

By Trading Economics

Income

53M

-46M

Sales

-8.8M

56M

EPS

-0.02

Profit margin

-82.429

Employees

570

EBITDA

127M

-21M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+135.59% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-66M

600M

Previous open

5.31

Previous close

2.14

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

1 Apr 2025, 23:15 UTC

Major Market Movers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1 Apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1 Apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1 Apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1 Apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1 Apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Apr 2025, 20:20 UTC

Top News

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eaton Completes Acquisition Of Fibrebond >ETN

1 Apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1 Apr 2025, 20:07 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 Apr 2025, 19:46 UTC

Top News

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1 Apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1 Apr 2025, 19:17 UTC

Top News

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1 Apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1 Apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1 Apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1 Apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

1 Apr 2025, 18:51 UTC

Market Talk

Weaker Dollar Could Add Headwinds for Airlines -- Market Talk

1 Apr 2025, 18:47 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Stock Rebounds From Selloff. Count On More Volatility. -- Barrons.com

1 Apr 2025, 18:07 UTC

Top News

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 Apr 2025, 17:16 UTC

Market Talk

Oil Futures Slip From Five-Week Highs -- Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Trump Tariff Plans Look Counterproductive for Industry -- Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Economists Lower Mexico GDP Growth Estimates -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

135.59% upside

12 Months Forecast

Average 5.56 USD  135.59%

High 10 USD

Low 2.5 USD

Based on 10 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

2.19 / 2.42Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.